0578 Feasibility and Preliminary Efficacy of WePAP, a Dyadic Transdiagnostic Intervention

Abstract Introduction The goal of this study was to examine feasibility, acceptability, and preliminary efficacy of WePAP, a novel, couples-based treatment to promote positive airway pressure (PAP) adherence in patients with obstructive sleep apnea (OSA) and sleep quality in patients and partners. Methods Patients who were recently diagnosed with OSA and starting PAP and their partners completed pre- and post-treatment self-report measures of study constructs and actigraphy. Couples were randomly assigned to WePAP or information control (IC) groups. Post-PAP assessments and adherence downloads were completed at 1 and 3 months. The main outcomes were feasibility and acceptability ratings. Preliminary efficacy outcomes included: patient PAP adherence and subjective and actigraphy-assessed sleep in patients and partners. Secondary outcomes included depression, quality of life, relationship, and cognitive functioning. Results The study enrolled 37 couples (age m= 62.97; SD=9.04). All WePAP couples attended each of the three sessions. Compared to the IC group, patients and partners in WePAP rated the intervention more favorably and were more satisfied. Among the primary efficacy outcomes, PAP adherence was high in both groups (PAP use >4 h= 85% in WePAP and 77% in IC). There were significant within-group differences for subjective sleep, such that patients in both groups showed significant reductions in sleep disturbance at 3-months. In addition, patients in both groups and partners in WePAP showed significant reductions in sleep related impairment at 3-months. Among secondary outcomes, patients in both WePAP and IC showed significant improvements in depression and QOL. WePAP patients also showed small but significant improvements in a measure of processing speed and attention. There were no within- or between-group changes in relationship quality. Conclusion Results demonstrate that WePAP is feasible and well-liked by patients and partners, but did not demonstrate greater adherence or improved sleep quality in this sample of highly adherent patients. Future studies should examine longer-term outcomes and enroll patients at greater risk for non-adherence to PAP. Support (if any) The research reported in this publication was supported (in part or in full) by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers R21AG067183 (PIs: Baron and Troxel), 3R21AG067183-01A1S1 (Baron/DeVettori), UL1TR002538 and UM1TR004409.